Solventum (NYSE:SOLV) Shares Break Below 50-Day Moving Average - Here's Why

Solventum logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Solventum shares fell below their 50-day moving average of $87.39, reaching $86.03 and last trading at $86.24.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $90.27; recent views were mixed, including upgrades and a downgrade.
  • Quarterly EPS of $1.45 and revenue of $1.95 billion beat estimates, but revenue declined 7% year over year.
  • Five stocks we like better than Solventum.

Solventum Corporation (NYSE:SOLV - Get Free Report)'s share price passed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $87.39 and traded as low as $86.03. Solventum shares last traded at $86.2350, with a volume of 725,311 shares.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Zacks Research raised Solventum from a "hold" rating to a "strong-buy" rating in a research note on Thursday, November 12th. KeyCorp lifted their price target on Solventum from $93.00 to $102.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Wedbush lifted their price target on Solventum from $94.00 to $101.00 and gave the stock an "outperform" rating in a research report on Thursday, August 6th. Weiss Ratings cut shares of Solventum from a "buy (b-)" rating to a "hold (c-)" rating in a research note on Monday, November 9th. Finally, Stifel Nicolaus increased their price objective on shares of Solventum from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $90.27.

Check Out Our Latest Stock Analysis on Solventum

Solventum Stock Performance

The company has a market capitalization of $14.64 billion, a PE ratio of 96.89, a price-to-earnings-growth ratio of 1.26 and a beta of 0.69. The business's fifty day moving average is $87.39 and its two-hundred day moving average is $79.06. The company has a current ratio of 1.03, a quick ratio of 0.72 and a debt-to-equity ratio of 0.99.

Solventum (NYSE:SOLV - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.11. The business had revenue of $1.95 billion for the quarter, compared to analysts' expectations of $1.93 billion. Solventum had a net margin of 1.91% and a return on equity of 25.03%. The business's revenue for the quarter was down 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.50 EPS. Equities research analysts predict that Solventum Corporation will post 7.26 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SOLV. Laurel Wealth Advisors LLC bought a new stake in Solventum in the 3rd quarter worth approximately $29,000. JNBA Financial Advisors lifted its holdings in shares of Solventum by 71.9% during the 2nd quarter. JNBA Financial Advisors now owns 507 shares of the company's stock valued at $39,000 after buying an additional 212 shares during the period. Ameritas Advisory Services LLC bought a new position in shares of Solventum during the 2nd quarter valued at $47,000. Ancora Advisors LLC bought a new position in shares of Solventum during the 2nd quarter valued at $56,000. Finally, Root Financial Partners LLC purchased a new position in shares of Solventum in the 3rd quarter worth $68,000.

About Solventum

(Get Free Report)

Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M's healthcare business and became an independent public company in April 2024. The company's offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Solventum Right Now?

Before you consider Solventum, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.

While Solventum currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines